News

Title Content Date
Data Published in Nature Biotechnology Show Messenger (m)RNA Prophylactic Vaccines Based on CureVac’s RNActive® Technology Demonstrate Immunogenicity and Protection Against Influenza Virus Infection CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German Federal Research Institute for Animal Health, Friedrich-Loeff 27.11.2012
Cell Culture Made Easy – InnoCyte GmbH Finds Further Investors InnoCyte GmbH has developed a technology that standardizes, automates, accelerates and therefore significantly simplifies and reduces the cost of producing biological cells. 22.11.2012
Amplexa genetics and CeGaT enter into collaborative partnership The partnership will see both companies exchanging their expertise and knowledge as well as validated genetic tests for their respective patients. 19.11.2012
How bacteria attack their host cells with sticky lollipops Yersinia enterocolitica, a pathogenic bacterium, causes fever and diarrhea. By help of a protein anchored in its membrane, Yersinia attaches to its host cells and infects them. 13.11.2012
immatics appoints Peter Chambré as Chairman immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced the appointment of Peter Chambré a 12.11.2012
CeGaT and Genomatix finalists of Boston Children's Hospital's CLARITY challenge CeGaT (Center for Genomics and Transcriptomics) GmbH, the Department of Prostate Cancer Research, Institute of Pathology, University Hospital Bonn and Genomatix Software GmbH were announced as fina 08.11.2012
CeGaT and Genomatix finalists of Boston Children’s Hospital’s CLARITY challenge San Francisco, Tuebingen, Munich, November 7, 2012 - CeGaT (Center for Genomics and Transcriptomics) GmbH, the Department of Prostate Cancer Research, Institute of Pathology, University Hospital Bo 08.11.2012
immatics’ renal cancer vaccine IMA901 completes phase 3 patient recruitment and is granted US orphan drug designation by the FDA immatics biotechnologies GmbH, a biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer, announced today that it has completed patient recruitm 08.11.2012
Delegation from Latin America visits BioRegio STERN It was a challenge to present the region’s main fields of expertise to guests from abroad in only two hours. 17.10.2012
Genedata and Insilico Biotechnology Integrate Industrial Biotechnology Platforms Genedata, a leading provider of advanced software solutions for industrial biotechnology, drug discovery and life science research, and Insilico Biotechnology, a premier provider of advanced soluti 02.10.2012

Pages